

Have you or someone you know been diagnosed with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)?

Consider enrolling in the **TakeAim Leukemia trial** - a clinical research study evaluating emavusertib alone or in combination with azacitidine or venetoclax. The study is evaluating the effects of these treatment on Higher-Risk Myelodysplastic Syndrome (hrMDS) or Acute Myeloid Leukemia (AML).

Emavusertib is an investigational drug that is not approved by the FDA or other global health authorities in AML or MDS. Safety and efficacy have not been established.

The CURIS logo features a stylized blue eye icon above the word "CURIS" in a blue serif font, with a registered trademark symbol (®) to the upper right.The TakeAim logo consists of a blue swoosh above the word "TakeAim" in a blue sans-serif font, with a small blue dot at the end of the swoosh.

Contact your doctor to discuss participating in this clinical trial. For more information about emavusertib (CA-4948) visit ClinicalTrials.gov and search (NCT04278768).